PCL5 Antibody

What mechanisms drive antibody internalization in target cells?

Antibody internalization occurs through several pathways, with receptor-mediated mechanisms being particularly significant in research applications. The neonatal Fc receptor (FcRn) plays a critical role in this process. For example, studies with the 11B6 antibody (targeting free hK2) demonstrate that FcRn mediates the internalization of secreted antigen-targeted antibodies (SATAs) . This internalization mechanism involves the binding of antibody-antigen complexes, followed by pH-dependent interactions with FcRn in endosomes, which facilitates intracellular accumulation. This process has been confirmed through confocal microscopy of prostate tissue from transgenic mice and cell line studies .

How do antigen-antibody complex properties affect internalization efficiency?

The physical and biochemical properties of antigen-antibody complexes significantly influence internalization efficiency. Research indicates that residues at the constant heavy chain 2 and 3 (CH2/CH3) junction contribute to the pH-dependent affinity of IgG interaction with FcRn . This characteristic is critical for effective internalization, as demonstrated in comparative studies between different antibodies. For example, when the complementarity-determining regions (CDRs) of the 5A10 antibody (which targets free PSA) were grafted onto the 11B6 Fc scaffold, researchers observed steadily increasing tumor uptake compared to the original antibody construct . This highlights how structural modifications to the antibody can enhance internalization and retention in target tissues.

What are the key considerations when developing antibodies against secreted antigens?

When developing antibodies against secreted antigens, researchers must consider several critical factors:

• Washout effects: Traditional antibodies directed to secreted antigens often show poor retention at disease sites due to washout of antibody-bound complexes from the target location .

• Internalization mechanisms: For effective imaging or therapeutic applications, antibodies should ideally be internalized by target cells. FcRn-mediated uptake represents a promising mechanism for enhancing antibody retention .

• Target specificity: The ideal secreted antigen target should have restricted expression in specific tissues or disease states. For example, human kallikrein-related peptidase 2 (free hK2) shows prostate tissue-specific expression, making it a suitable target for prostate cancer applications .

• Antibody engineering: Structural modifications to enhance binding, internalization, or other functional properties may be necessary for optimal performance. This might involve alterations to the Fc region or complementarity-determining regions .

How can antibody internalization be leveraged for imaging and therapeutic applications?

Antibody internalization offers powerful opportunities for both imaging and therapeutic applications through several mechanisms:

• Enhanced target retention: Internalized antibodies accumulate within target cells, providing stronger and more persistent signals for imaging applications. For example, 11B6 antibody shows intracellular accumulation in prostate cancer cells, allowing for non-invasive assessment of androgen receptor pathway activity .

• Improved signal-to-noise ratio: Internalization reduces background signal by clearing non-bound antibodies from circulation while retaining target-specific antibodies in cells of interest. This has been demonstrated in studies using fluorescent and radioactive conjugates of antibodies like 11B6 .

• Therapeutic payload delivery: Internalization facilitates the delivery of conjugated therapeutic agents (cytotoxic drugs, radionuclides) directly into target cells, enhancing efficacy while reducing systemic toxicity.

• Reporting receptor activity: Internalized antibodies can serve as reporters of receptor pathway activity. For instance, internalized 11B6 antibody provides a non-invasive means to monitor androgen receptor pathway activation in prostate cancer .

This approach shows particular promise for monitoring treatment response, as demonstrated in castration-resistant tumor xenografts, where uptake measurements can help assess patients who have failed hormone therapy .

What strategies can overcome challenges associated with pre-existing antibodies in therapeutic applications?

Pre-existing antibodies present significant challenges for therapeutic antibody development, as demonstrated in clinical trials with bacterial proteins like CHIPS. Several strategies can help address these issues:

• Antibody engineering and humanization: Modifying the antibody structure to reduce immunogenicity while maintaining functionality. This involves removing or altering epitopes commonly recognized by pre-existing antibodies .

• Pre-screening patients: Determining the titers of pre-existing antibodies in potential recipients before administration. In the CHIPS clinical trial, researchers measured anti-CHIPS antibody titers in subjects before treatment, though they underestimated the impact of even "low" antibody levels .

• Dose adjustment strategies: Implementing personalized dosing regimens based on pre-existing antibody titers. Higher doses may be required for patients with higher pre-existing antibody levels to achieve therapeutic target engagement.

• Alternative administration routes: Exploring delivery methods that might reduce exposure to circulating antibodies or enhance local concentration at target sites.

• Combination with immunomodulatory agents: Co-administering agents that temporarily suppress immune responses against the therapeutic antibody.

Research with CHIPS protein demonstrates the critical importance of addressing pre-existing antibodies - despite promising results in human C5AR1 knock-in mice, human subjects showed adverse effects linked to pre-existing anti-CHIPS antibodies, including clinical signs of anaphylaxis, mild leukocytopenia, and increased C-reactive protein concentrations .

What computational methods are most effective for predicting antibody-antigen binding?

Current computational methods for predicting antibody-antigen binding include:

• Machine learning models for many-to-many relationships: These approaches analyze multiple antibodies against multiple antigens simultaneously, enabling prediction of specific interacting pairs . This is particularly valuable for library-on-library screening approaches.

• Active learning strategies: These methods start with a small labeled dataset and iteratively expand it, significantly reducing experimental costs. Recent research has identified three algorithms that outperform baseline approaches for out-of-distribution prediction scenarios .

• Simulation frameworks: Tools like the Absolut! simulation framework enable evaluation of prediction algorithms using synthetic data before expensive experimental validation .

These approaches are particularly valuable when addressing out-of-distribution prediction challenges - cases where test antibodies and antigens are not represented in the training data . This scenario is common in novel antibody development and requires specialized computational strategies.

How can we evaluate antibody-target binding in vivo versus ex vivo?

Evaluating antibody-target binding involves complementary in vivo and ex vivo approaches:

In vivo methods:

• Radioactive or fluorescent tracing: Conjugated antibodies can be tracked after administration to detect binding to target tissues. The 11B6 antibody demonstrates high concordance between intravenously administered fluorescent and radioactive tracers .

• Whole-body imaging: Techniques like PET scanning with 89Zr-labeled antibodies can non-invasively track antibody distribution and target engagement over time .

• Blood sampling for antibody clearance: Measuring serum antibody concentration over time provides pharmacokinetic data. For example, CHIPS protein showed a calculated half-life of approximately 1.5 hours in humans .

Ex vivo methods:

• Flow cytometry of harvested cells: In both the CHIPS and 11B6 studies, researchers analyzed neutrophils or tumor cells for antibody binding using flow cytometry .

• Confocal microscopy: Tissue sections from animal models can be analyzed for antibody localization and internalization. Video microscopy has confirmed the uptake of 11B6 by epithelial cells in prostatic ducts .

• Single-cell analysis: Cells extracted from target tissues can be analyzed for fluorescent antibody uptake, as demonstrated with the 11B6 antibody .

What animal models are most appropriate for testing antibody species specificity?

When testing antibodies with species-specific binding properties, selecting appropriate animal models is critical:

• Humanized receptor knock-in mice: For antibodies with human-specific targets, transgenic mice expressing the human version of the target protein provide valuable models. For example, human C5AR1 knock-in mice were essential for evaluating CHIPS, which has 30-fold lower activity against mouse C5ar1 compared to human C5AR1 .

• Validation of target expression: Confirm that the humanized receptor functions similarly to the human version in the mouse model. Researchers verified that CHIPS binds to bone marrow-derived hC5aR1 KI murine neutrophils at levels comparable to human neutrophils .

• Functional assays: Verify that the antibody affects the expected biological functions in the model. For the CHIPS protein, researchers confirmed inhibition of mC5a-mediated Ca mobilization in hC5aR1 KI neutrophils, reflecting the behavior observed with human neutrophils .

• Disease-specific models: For therapeutic applications, incorporate disease models that recapitulate key aspects of human pathology. The immune complex-mediated Arthus reaction model was used to evaluate CHIPS in hC5aR1 KI mice, as the resulting inflammatory response is primarily C5a-mediated .

When designed appropriately, these models can effectively bridge the gap between in vitro characterization and human clinical trials.

How should researchers evaluate potential immunogenicity of therapeutic antibodies?

Evaluating the immunogenicity of therapeutic antibodies requires a multi-tiered approach:

• Pre-existing antibody screening in target populations:

  • Perform ELISA testing on serum samples from diverse donor populations to determine the prevalence and titer of pre-existing antibodies

  • Establish threshold titers that correlate with potential clinical effects

  • In the CHIPS trial, researchers established a titer threshold (log of serum dilution giving an absorbance of 0.300 in ELISA) but underestimated the clinical significance of even "low" titers

• In vitro neutralization assays:

  • Test whether pre-existing antibodies neutralize the therapeutic function in relevant cellular assays

  • The CHIPS study demonstrated that even low levels of anti-CHIPS antibodies in rabbit IgG could partially neutralize CHIPS activity in vitro

• Immunogenicity testing in animal models:

  • Monitor antibody responses in relevant animal models after single and repeated dosing

  • Track both binding and neutralizing antibody development

• Post-administration monitoring:

  • Measure changes in antibody titers following administration

  • The CHIPS human trial showed rapid boosting of anti-CHIPS titers in subjects with initially low titers, indicating pre-existing memory responses

• Antibody epitope mapping:

  • Identify specific regions of the therapeutic antibody recognized by pre-existing antibodies

  • This information can guide protein engineering efforts to reduce immunogenicity

What controls should be included when evaluating antibody specificity and internalization?

Proper controls are essential for rigorous evaluation of antibody specificity and internalization:

• Target knockout/knockdown controls:

  • Cells or tissues lacking the target protein through genetic modification

  • Provides definitive negative control for binding specificity

  • The 11B6 study used wild-type versus transgenic mouse tissues expressing human KLK2

• Competitive binding controls:

  • Pre-incubation with unlabeled antibody or known ligands

  • Confirms binding site specificity and receptor-mediated uptake

• Isotype-matched control antibodies:

  • Antibodies of the same isotype but different specificity

  • Controls for Fc-mediated effects independent of target binding

• Structure-function variants:

  • Modified versions of the antibody with altered binding properties

  • The study comparing 5A10 and modified 5A10 H435-wt demonstrated how structural modifications affect internalization

• Temperature controls:

  • Comparing uptake at 37°C versus 4°C

  • Distinguishes active internalization from surface binding

• Cross-species reactivity:

  • Testing on cells/tissues from multiple species

  • Identifies species-specific binding properties, as demonstrated with CHIPS showing 30-fold lower activity on mouse versus human C5ar1

• Subcellular localization tracking:

  • Co-localization with endosomal markers

  • Confirms internalization pathway and intracellular trafficking

These controls ensure that observed effects are specifically due to target-mediated antibody internalization rather than non-specific binding or uptake mechanisms.

How can active learning approaches improve antibody development efficiency?

Active learning approaches offer significant advantages for antibody development by optimizing the selection of experimental conditions:

• Reducing experimental costs and time:

  • Start with a small labeled dataset and iteratively expand based on model uncertainty

  • Particularly valuable for library-on-library screening approaches where testing all combinations would be prohibitively expensive

• Addressing out-of-distribution prediction challenges:

  • Specialized algorithms help predict binding for antibodies and antigens not represented in training data

  • Recent research identified three algorithms that significantly outperformed baseline approaches for this scenario

• Simulated evaluation frameworks:

  • Tools like Absolut! allow testing of active learning strategies before committing to expensive experimental validation

  • These simulations help identify the most promising algorithms for specific antibody research contexts

• Optimizing sampling strategies:

  • Balance exploration (testing diverse antibody-antigen pairs) with exploitation (focusing on promising candidates)

  • Recent research evaluated fourteen novel active learning strategies specifically for antibody-antigen binding prediction

• Integrating computational and experimental workflows:

  • Create feedback loops between prediction algorithms and experimental validation

  • Continuously refine models based on new experimental data

This approach is particularly valuable for developing antibodies against novel targets where limited prior binding data exists, potentially accelerating therapeutic antibody discovery while minimizing resource investment.

What factors determine successful translation of antibody therapies from animal models to human trials?

Successful translation of antibody therapies from animal models to humans depends on several critical factors:

• Species-specific target binding differences:

  • Antibodies often show different binding affinities across species

  • The CHIPS protein demonstrated 30-fold lower activity against mouse C5ar1 compared to human C5AR1

  • Humanized animal models can bridge this gap, as demonstrated with the human C5AR1 knock-in mice used for CHIPS evaluation

• Pre-existing immunity assessment:

  • The presence of pre-existing antibodies can significantly impact clinical outcomes

  • In the CHIPS clinical trial, even subjects with "low" anti-CHIPS antibody titers showed adverse effects, including anaphylaxis symptoms

  • Thorough screening of target populations before clinical trials is essential

• Target distribution and accessibility:

  • Differences in target protein expression patterns between animal models and humans

  • The 11B6 study demonstrated how antibodies against secreted antigens can be internalized in specific tissues expressing the target

  • Comprehensive biodistribution studies are needed before human trials

• Antibody clearance and half-life:

  • Species differences in antibody clearance mechanisms

  • CHIPS protein showed a calculated half-life of approximately 1.5 hours in humans

  • Pharmacokinetic studies must inform dosing strategies for human trials

These considerations highlight the importance of comprehensive preclinical evaluation using appropriate animal models and extensive characterization of potential immunogenicity before advancing to human trials.

[Data Table: Factors Affecting Translation Success]